PepGen Inc. (PEPG)
NASDAQ: PEPG
· Real-Time Price · USD
1.58
0.11 (7.48%)
At close: May 02, 2025, 3:59 PM
1.52
-4.08%
After-hours: May 02, 2025, 04:09 PM EDT
Company Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases.
The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD).
It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD.
The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PepGen Inc.
| Country | United States |
| IPO Date | May 6, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Dr. James G. McArthur Ph.D. |
Contact Details
Address: 245 Main Street Cambridge, Massachusetts United States | |
| Website | https://www.pepgen.com |
Stock Details
| Ticker Symbol | PEPG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001835597 |
| CUSIP Number | 713317105 |
| ISIN Number | US7133171055 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. James G. McArthur Ph.D. | President, Chief Executive Officer, Treasurer, Secretary & Director |
| Noel P. Donnelly M.B.A. | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 22, 2025 | 4 | Filing |
| Apr 09, 2025 | 4 | Filing |
| Mar 31, 2025 | 8-K | Current Report |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 4 | Filing |
| Mar 31, 2025 | 3 | Filing |
| Mar 31, 2025 | 3 | Filing |